Traitement curatif de la maladie thromboembolique veineuse chez les patients atteints de cancer : quelle place pour les anticoagulants oraux directs en 2018 ?

Farge, 2013, International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, J Thromb Haemost, 11, 56, 10.1111/jth.12070 Debourdeau, 2013, International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer, J Thromb Haemost, 11, 71, 10.1111/jth.12071 Farge, 2016, International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer, Lancet Oncol, 17, e452, 10.1016/S1470-2045(16)30369-2 Benzidia, 2017, New international guidelines for curative treatment and prophylaxis for venous thromboembolism (VTE) in cancer patients and the dedicated smartphone application, J Med Vasc, 42, 375 Meyer, 2002, Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study, Arch Intern Med, 162, 1729, 10.1001/archinte.162.15.1729 Lee, 2003, N Engl J Med, 349, 146, 10.1056/NEJMoa025313 Hull, 2006, LITE trial investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer, Am J Med, 119, 1062, 10.1016/j.amjmed.2006.02.022 Deitcher, 2006, ONCENOX investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period, Clin Appl Thromb, 12, 389, 10.1177/1076029606293692 Lee, 2015, Tinzaparin vs Warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial, JAMA, 314, 677, 10.1001/jama.2015.9243 Schulman, 2009, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, 2342, 10.1056/NEJMoa0906598 Schulman, 2014, Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation, 129, 764, 10.1161/CIRCULATIONAHA.113.004450 Investigators EINSTEIN, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903 EINSTEIN-PE Investigators, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, 1287, 10.1056/NEJMoa1113572 Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507 Investigators Hokusai-VTE, 2013, Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med, 369, 1406, 10.1056/NEJMoa1306638 Haute Autorité de santé, 2018 Khorana, 2016, Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?, Thromb Res, 145, 51, 10.1016/j.thromres.2016.07.013 Khorana, 2017, Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis, Res Pract Thromb Haemost, 1, 14, 10.1002/rth2.12002 Khorana, 2017, VTE recurrence and safety of anticoagulants among patients with cancer treated for venous thromboembolism, Blood, 130, 4631 Benzidia, 2018, Mésusage et iatrogénie des anticoagulants oraux directs chez les patients atteints de cancer : à propos de trois cas, J Med Vasc, 43, 139 Mahé, 2017, Prevention and treatment of cancer-associated thrombosis in France: a national survey among vascular disease and supportive care specialists, J Med Vasc, 42, 255 Prandoni, 2002, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis, Blood, 100, 3484, 10.1182/blood-2002-01-0108 Short, 2014, New oral anticoagulants and the cancer patient, Oncologist, 19, 82, 10.1634/theoncologist.2013-0239 Becattini, 2016, Treatment of venous thromboembolism with new anticoagulant agents, J Am Coll Cardiol, 67, 1941, 10.1016/j.jacc.2016.01.072 Vedovati, 2015, Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis, Chest, 147, 475, 10.1378/chest.14-0402 Streiff, 2018, Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer, Am J Hematol, 93, 664, 10.1002/ajh.25059 Phelps, 2016, Comparison of direct oral anticoagulants versus low-molecular-weight-heparins for the treatment of cancer associated thrombosis, Blood, 128, 5013, 10.1182/blood.V128.22.5013.5013 Seo, 2016, Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer, Ann Oncol, 27, 695, 10.1093/annonc/mdw371.87 Ageno, 2017, Subgroup analysis of patients with cancer in XALIA: a noninterventional study of rivaroxaban versus standard anticoagulation for VTE, TH Open, 01, e33, 10.1055/s-0037-1603924 Alzghari, 2017, Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study, J Oncol Pharm Pract, 10.1177/1078155217718382 Chaudhury, 2017, The efficacy and safety of Rivaroxaban and Dalteparin in the treatment of cancer associated venous thrombosis, Indian J Hematol Blood Transfus, 1 Ross, 2017, Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis, Thromb Res, 150, 86, 10.1016/j.thromres.2016.12.016 Signorelli, 2017, Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: a pilot study, J Oncol Pharm Pract, 10.1177/1078155217739683 Hummert, 2017, Comparative evaluation of the safety and effectiveness of rivaroxaban (riva) and enoxaparin (enox) for treatment of venous thromboembolism (VTE) in cancer patients, J Clin Oncol, 35, e18268, 10.1200/JCO.2017.35.15_suppl.e18268 Rahman, 2017, Treatment of cancer associated venous thrombosis: the Cleveland clinic experience, Blood, 130, 4633 McBane, 2016, Rivaroxaban compared to low molecular weight heparin in treatment of malignancy associated venous thromboembolism, J Am Coll Cardiol, 67, 2257, 10.1016/S0735-1097(16)32258-6 Beyer-Westendorf, 2018, What have we learned from real-world NOAC studies in venous thromboembolism treatment?, Thromb Res, 163, 83, 10.1016/j.thromres.2018.01.034 Raskob, 2018, Hokusai VTE cancer investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism, N Engl J Med, 378, 615, 10.1056/NEJMoa1711948 Young, 2018, Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D), J Clin Oncol Schulman, 2005, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost, 3, 692 Li, 2018, Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis, Thromb Res, 10.1016/j.thromres.2018.02.144